The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Trastuzumab: triumphs and tribulations
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 2×
“Overexpression of HER2, with subsequent constitutive kinase activation, is found in approximately 20–30p of human breast cancers, primarily owing to gene amplification, and is associated with reduced disease-free and overall survival (”
BackgroundSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 5×
“The majority of MBC patients who initially respond to trastuzumab begin to demonstrate disease progression again within 1 year (Seidman et al., 2001; Slamon et al., 2001; Esteva et al., 2002).”
BackgroundInfluentialStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 5×
“Mice with suppressed natural killer (NK) cell function, which is important for ADCC, demonstrated only 29% tumor growth inhibition in response to trastuzumab versus 96% tumor growth inhibition in control mice with intact NK cell function (Clynes et al., 2000).”
BackgroundInfluentialCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 946
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Self-citationKonecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · cited 1×
“The result is disruption of HER2/EGFR and HER2/HER3 with decreased downstream signaling (Agus et al., 2002; Nahta et al., 2004a).”
BackgroundPress, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Self-citationYakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Nahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607
Self-citationEsteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566
Self-citationSeidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Self-citationArnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0225 · Cited by 516
Herceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Self-citationAdams, C. W., Allison, D. E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKeever, K., & Sliwkowski, M. X. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316
Christianson, T. A., Doherty, J. K., Lin, Y.-J., Ramsey, E. E., Holmes, R. S., Keenan, E. J., & Clinton, G. M. (1998) · PubMed · Cited by 302
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298 · cited 6×
“By developing an in vitro model of resistance by chronic exposure of SKBR3 cells to trastuzumab (”
BackgroundInfluentialSelf-citationLane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Tanner, M., Kapanen, A. I., Junttila, T., Raheem, O., Grenman, S., Elo, J., Elenius, K., & Isola, J. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1585.3.12 · Cited by 273
Xia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258
Mechanism of action of trastuzumab and scientific update
BASELGA, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90276-3 · Cited by 258
Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hösch, S., & Hayes, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2518 · Cited by 239
Molina‐Vila, M. Á., Sáez, R., Ramsey, E. E., Garcia-Barchino, M. J., Rojo, F., Evans, A. J., Albanell, J., Keenan, E. J., Lluch, A. M., García-Conde, J., et al. (2002) · PubMed · Cited by 232
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Anido, J., Scaltriti, M., Bech Serra, J. J., Josefat, B. S., Rojo Todo, F., Baselga, J., & Arribas, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601191 · Cited by 231
Cooley, S., Burns, L. J., Repka, T., & Miller, J. S. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00089-2 · Cited by 213 · cited 4×
“Mice with suppressed natural killer (NK) cell function, which is important for ADCC, demonstrated only 29% tumor growth inhibition in response to trastuzumab versus 96% tumor growth inhibition in control mice with intact NK cell function (Clynes et al., 2000).”
BackgroundInfluentialLu, Y., Zi, X., & Pollak, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.11445 · Cited by 208
Zabrecky, J. R., Lam, T., McKenzie, S. J., & Carney, W. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52354-1 · Cited by 201
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
Neve, R. M., Sutterlüty, H., Pullen, N., Lane, H. A., Daly, J. M., Krek, W., & Hynes, N. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203470 · Cited by 180
Le, X., Claret, F.-X., Lammayot, A., Tian, L., Deshpande, D. M., LaPushin, R., Tari, A. M., & Bast, R. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300848200 · Cited by 178
Wen, X.-F., Yang, G., Mao, W., Thornton, A., Liu, J., Bast, R. C., & Le, X.-F. (2006) · Oncogene · doi:10.1038/sj.onc.1209685 · Cited by 159
Esteva, F. J., Cheli, C. D., Fritsche, H. A., Fornier, M. N., Slamon, D. J., Thiel, R. P., Lüftner, D., & Ghani, F. (2005) · Breast Cancer Research · doi:10.1186/bcr1020 · Cited by 154
Self-citationBurstein, H. J., Lieberman, G. S., Slamon, D. J., Winer, E. P., & Klein, P. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi371 · Cited by 149
Köstler, W. J., Schwab, B., Singer, C. F., Neumann, R., Rücklinger, E., Brodowicz, T., Tomek, S., Niedermayr, M., Hejna, M., Steger, G. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0385-3 · Cited by 143
Klos, K. S., Zhou, X., Lee, S., Zhang, L., Yang, W., Nagata, Y., & Yu, D. (2003) · Cancer · doi:10.1002/cncr.11656 · Cited by 111
Jerome, L., Alami, N., Belanger, S., Pagé, V., Yu, Q., Paterson, J., Shiry, L., Pegram, M. D., & Leyland-Jones, B. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3555 · Cited by 111
Camirand, A., Lu, Y., & Pollak, M. (2002) · PubMed · Cited by 98
Hayes, D. F., Yamauchi, H., Broadwater, G., Cirrincione, C., Rodrigue, S. P., Berry, D. A., Younger, J., Panasci, L., Millard, F. E., Duggan, D. B., et al. (2001) · PubMed · Cited by 95
DiGiovanna, M. P., & Chakraborty, A. K. (2006) · Cancer Research · Cited by 6
Cited by
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00001 · Cited by 531
Metadata
- Authors
- Nahta, R., & Esteva, F. J.
- Venue
- Oncogene
- Published
- 2007-05-28
- Volume
- 26
- Issue
- 25
- Pages
- 3637-3643
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2068449976
- Cited by
- 334
- References
- 56
- FWCI
- 15.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.